Kliniken & Institute ... Kliniken Zentrum für Innere... Innere Medizin III:... Forschung Section of Molecular... Publikationen

Publikationen

Weber C1, Neacsu I1, Krautz B1, Schlegel P2, Sauer S3, Raake P2, Ritterhoff J1, Jungmann A2, Remppis AB2, Stangassinger M4, Koch WJ5, Katus HA6, Müller OJ2, Most P7, Pleger ST1.
Therapeutic safety of high myocardial expression levels of the molecular inotrope S100A1 in a preclinical heart failure model.
Gene Ther. 2014 Feb;21(2):131-8. doi: 10.1038/gt.2013.63. Epub 2013 Dec 5.

Rohde D1, Schön C1, Boerries M2, Didrihsone I1, Ritterhoff J1, Kubatzky KF3, Völkers M1, Herzog N1, Mähler M1, Tsoporis JN4, Parker TG4, Linke B5, Giannitsis E1, Gao E6, Peppel K6, Katus HA7, Most P8.
S100A1 is released from ischemic cardiomyocytes and signals myocardial damage via Toll-like receptor 4.  EMBO Mol Med. 2014 May 15/ ncbi.nih.gov/pubmed

Sven T. Pleger, H. Brinks, J. Ritterhoff, P. Raake, W.J. Koch, H.A. Katus, P. Most
Heart Failure Gene Therapy: The Path to Clinical Practice
Circ Res. 2013 Aug 30; 113:792-809.

Most P, Lerchenmüller C, Rengo G, Mahlmann A, Ritterhoff J, Rohde D, Goodman C, Busch CJ, Laube F, Heissenberg J, Pleger ST, Weiss N, Katus HA, Koch WJ, Peppel K.
S100A1 deficiency impairs postischemic angiogenesis via compromised proangiogenic endothelial cell function and nitric oxide synthase regulation.
Circ Res. 2013 Jan 4;112(1):66-78.

Most P, Raake P, Weber C, Katus HA, Pleger ST.
S100A1 Gene Therapy in Small and Large Animals.
Methods Mol Biol. 2013;963:407-20.

Reinkober J, Tscheschner H, Pleger ST, Most P, Katus HA, Koch WJ, Raake PW.
Targeting GRK2 by gene therapy for heart failure: benefits above β-blockade.
Gene Ther. 2012 Jun;19(6):686-93.

Raake PW, Zhang X, Vinge LE, Brinks H, Gao E, Jaleel N, Li Y, Tang M, Most P, Dorn GW 2nd, Houser SR, Katus HA, Chen X, Koch WJ.
Cardiac G-protein-coupled receptor kinase 2 ablation induces a novel Ca2+ handling phenotype resistant to adverse alterations and remodeling after myocardial infarction.
Circulation. 2012 May 1;125(17):2108-18.

Völkers M, Dolatabadi N, Gude N, Most P, Sussman MA, Hassel D.
Orai1 deficiency leads to heart failure and skeletal myopathy in zebrafish.  
J Cell Sci. 2012 Feb 2. [Epub ahead of print] supplement

Raake PW, Schlegel P, Ksienzyk J, Reinkober J, Barthelmes J, Schinkel S, Pleger S, Mier W, Haberkorn U, Koch WJ, Katus HA, Most P*,**, Müller OJ*. (*senior author, ** corresponding author)  
AAV6.βARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model.
Eur Heart J. 2012 Jan 19. [Epub ahead of print]  PMID:22261894 [PubMed - as supplied by publisher]

Raake PW, Tscheschner H, Reinkober J, Ritterhoff J, Katus HA, Koch WJ, Most P.
Gene therapy targets in heart failure: the path to translation.
Clin Pharmacol Ther. 2011 Oct;90(4):542-53. 

Pleger S.T., Shan C., Ksienzyk J., Bekeredjian R., Boekstegers P., Hinkel R., Schinkel S., Leuchs B., Ludwig J., Qiu G., Weber Ch., Raake P., Koch W.J., Katus H.A., Müller O.J. and Most P.: 
Cardiac AAV9-S100A1 Gene Therapy Rescues Post-Ischemic Heart Failure in a Preclinical Large Animal Model
Sci Transl Med 2011

Brinks H., Rohde D., Völkers M., Qiu G., Pleger S.T., Herzog N., Rabinowitz J., Ruhparwar A., Silvestry S., Lerchenmüller C., Mather P.J., Eckhart A.D., Katus H.A., Carrel T., Koch W.J., Most P.:
S100A1 genetically-targeted therapy reverses dysfunction of human failing cardiomyocytes.
Journal of the American College of Cardiology, accepted 2011

Völkers M., Weidenhammer C., Herzog N., Qiu G., Spaich K., v.Wegner F., Peppel K., Müller O., Schinkel S., Rabinowitz J., Hippe H.J., Brinks H., Katus H.A., Koch W.J., Eckhart A.D., Friedrich O., Most P.: 
The inotropic peptide βARKct improves βAR Responsiveness in normal and failing cardiomyocytes through Gβg-mediated L-type calcium current disinhibition. 
Circulation Research 108: 27-39, 2011

Rohde D, Brinks H, Ritterhoff J, Qui G, Ren S, Most P.: 
S100A1 gene therapy for heart failure: A novel strategy on the verge of clinical trials. 
Journal of Molecular and Cellular Cardiology 50: 777-784, 2010

Rohde, D., Ritterhoff, J., Völkers, M., Katus, H.A., Parker T.G., Most, P.: 
S100A1: A multifaceted Therapeutic Target in Cardiovascular Disease.
Journal of Cardiovascular Translational Research 3: 525-537, 2010

Völkers, M., Salz, M., Herzog, N., Frank, D., Dolatabati, N., Frey, N., Gude, N., Friedrich, O., Koch, W.J., Katus, H.A., Sussman, M.A., Most, P.: 
Orai1 and Stim-1 regulate normal and hypertrophic growth in cardiomyocytes.
Journal of Molecular and Cellular Cardiology 48:1329-34, 2010 

Völkers, M., Rohde, D., Goodman, C., Most, P.: 
S100A1: A regulator of striated muscle sarcoplasmic reticulum calcium handling, sarcomeric and mitochondrial function. 
Journal of Biomedicine and Biotechnology 2010; 

Brinks H., Boucher M., Gao E., Chuprun J.K., Pesant S., Raake P.W., Huang Z.M., Wang X., Qiu G., Gumpert A., Harris D.M., Eckhart A.D., Most P., Koch W.J.: 
Level of G protein-coupled receptor kinase-2 determines myocardial ischemia/reperfusion injury via pro- and anti-apoptotic mechanisms. 
Circulation Research 2010 Oct 29;107(9):1140-9.. 

Luedde, M., Floegel, U., Knorr, M., Grundt, C., Hippe, H.J., Brors, B., Frank, D., Haselmann, U., Antony, C., Voelkers, M., Schrader, J., Most, P., Lemmer, B., Katus, H.A., Frey, N.: 
Decreased contractility due to energy deprivation in a transgenic rat model of hypertrophic cardiomyopathy 
Journal of Molecular Medicine 87, 411-422, 2009 

Kraus, C., Rohde, D., Weidenhammer, C., Gang, Q., Pleger, S.T., Voelkers, M., Boerries, M., Remppis, A., Katus, H.A., Most, P.: 
S100A1 in cardiovascular health and disease: Closing the gap between basic science and clinical therapy.  
Journal of Molecular and Cellular Cardiology 47: 445-455, 2009

Droste AS, Rohde D, Voelkers M, Filusch A, Bruckner T, Borst MM, Katus HA, Meyer FJ 
Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension 
Respir Res. 2009 Dec 30;10:129 

Most P, Lerchenmüller C, Rengo G, Mahlmann A, Ritterhoff J, Rohde D, Goodman C, Busch CJ, Laube F, Heissenberg J, Pleger ST, Weiss N, Katus HA, Koch WJ, Peppel K. 
S100A1 Deficiency Impairs Post-Ischemic Angiogenesis via Compromised Proangiogenic Endothelial Cell Function and Nitric Oxide Synthase Regulation. 
Circ Res. 2012 Oct 9.

Ritterhoff J, Most P.
Targeting S100A1 in heart failure.
Gene Ther. 2012 Jun;19(6):613-21

Harris, D.M., Chen, X., Pesant, S., Cohn, H.I., McDonnel, S.M., Boucher, M., Vinge, L.E., Raake, P., Moraca, S.R., Li, D., Most, P., Houser, R. H., Koch, W. J., Eckhart, A.D.: 
Inhibition of angiotensin II Gq signaling augments b-adrenergic receptor mediated effects in a renal artery stenosis model of high blood pressure.
Journal of Cellular and Molecular Cardiology 46: 100-107, 2009

Raake, P.W., Vinge, L.E., Gao, E., Boucher, M., Rengo, G., Chen, X., deGeorge, B.R. Jr., Matkovich, S., Houser, S.R., Most, P., Eckhart, A.D., Dorn, G.W. II, Koch, W.J.: 
G protein coupled receptor kinase 2 ablation in cardiac myocytes before and after myocardial infarction prevents heart failure.
Circulation Research 103: 413-422, 2008

Boucher, M., Pesant, S., Nanton, N., Lei, Y.H., Most, P., Eckhart, A.D., Koch, W.J., Gao, E.: 
Simultaneous administration of insulin-like growth factor-1 and darbepoetin alfa protects the rat myocardium against myocardial infarction and enhances angiogenesis. 
Clinical and Translational Science 1: 13-20, 2008

DeGeorge Jr., B., Rosenberg, M., Eckstein, V., Gao, E., Herzog, N., Katus, H.A., Koch, W.J., Frey, N., Most, P.: 
BMP-2 and FGF-2 synergistically facilitate adoption of a cardiac phenotype in somatic bone marrow c-kit+/sca-1+ stem cells.
Clinical and Translational Science 2: 116-125, 2008

Pleger, S.T., Harris, D.H., Shan, C., Vinge, L.E., Chuprun, J.K., Berzins, B., Pleger, W., Druckman, C., Voelkers, M., Heierhorst, J., Oie,. E, Remppis, A., Katus, H.A., Scalia, R., Eckhart, A.D. Koch, W.J., Most. P.: 
Endothelial S100A1 modulates vascular function via nitric oxide.
Circulation Research 102: 786-794, 2008 

Völkers, M., Loughrey, C.M., MacQuaide, N., Remppis, A., deGeorge, B., Koch, W.J., v.Wegner, F., Friederich, O., Katus, H.A., Fink, R.H.A., Smith, G.L., Most, P.: 
S100A1 decreases calcium spark frequency and alters their spatial characteristics in permeabilized ventricular cardiomyocytes.
Cell Calcium 41: 135-143, 2007

Most, P., Remppis, A., Pleger, S.T., Katus, H.A., Koch, W.J.:
S100A1: a novel inotropic regulator of cardiac performance: Transition from molecular physiology to pathophysiological relevance.
Am J Physiol Regulatory Integrative Comp Physiol 293: R568-577, 2007

Most, P.*, Börries, M.*, Gledhill, J.R., Walker, J.E., Katus, H.A., Koch, W.J., Ueli, A., Schoenenberger, C.A.: 
The Ca2+-dependent interaction of S100A1 with the F1-ATPase leads to an increased ATP content in cardiomyocytes.
Molecular and Cellular Biology 27: 4365-4373, 2007 (*shared first authorship)

Most, P.*, Pleger, S.T.*, Boucher, M., Soltys, S., Chuprun, J.K., Pleger, W., Gao, E., Rengo, G., Remppis, A., Katus, H.A., Eckhart, A.D., Rabinowitz, J.E., Koch, W.J.: 
Stable myocardial specific AAV6-S100A1 gene therapy results in chronical functional heart failure rescue.
Circulation 115: 2506-2515, 2007 (*shared first authorship) 

Müller OJ, Leuchs B, Pleger ST, Grimm D, Franz WM, Katus HA, Kleinschmidt JA.
Cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors.
Cardiovasc Res. 2006 Apr 1;70(1):70-8.

Pleger ST, Koch WJ. 
The yin and yang of increased beta-adrenergic signaling: beta1-adrenergic genetic poymorphism and protection against acute myocardial ischemic injury.
Am J Physiol Heart Circ Physiol. 2006 Apr;290(4):H1408-9. 

Most, P., Seifert, H., Gao, E.G., Funakoshi, H., Völkers, M., Heierhorst, J., Remppis, A., Pleger, S.T., deGeorge, B., Eckhart, A.D., Katus, H.A., Feldman, A.M., Koch, W.J.: 
Cardiac S100A1 protein levels determine contractile performance and propensity towards heart failure after myocardial infarction.
Circulation 114: 1258-1268, 2006

Most, P.*, Pleger, S.T.*, Heidt, B., Völkers, M., Hata J.A., Katus, H.A., Remppis, A., Koch, W.J.:
S100A1 gene transfer to myocardium.
European Journal Medical Research 11: 418-422, 2006. (*shared first authorship) 

Ehlermann, P., Eggers, K., Bierhaus, A., Most, P., Weichenhan, D., Greten, J., Nawroth, P.P., Katus, H.A., Remppis, A.: 
Increased proinflammatory endothelial response to S100A8/S100A9 after preactivation through advanced glycation end products.
Cardiovascular Diabetology 5: 1-9, 2006  

Rottbauer, W., Just, S., Trano, N., Wessels, G., Most, P., Katus, H.A., Fishman, M.C.:
VEGF-PLCg1 pathway controls cardiac contractility in the embryonic heart.
Genes and Development 19: 1624-1634, 2005. 

Pleger ST*, Remppis A* Heidt B*, Völkers M, Chuprun JK, Kuhn M, Zhou   RH, Gao E, Szabo G, Weichenhan D, Müller OJ, Eckhart AD, Katus HA, Koch WJ, Most P. 
S100A1 gene therapy preserves in vivo cardiac function after myocardial infarction.
Mol Ther. 2005 Dec;12(6):1120-9.

Pleger ST, Koch WJ.
Translational medicine in genetic familial diseases: from the autopsy room to the molecular bench and vice versa
Hum Pathol. 2005 Jul;36(7):708-9. 

Pleger, S.T., Remppis, A., Heidt, B., Völkers, M., Gao, E., Chaprun, J.K., Szabo, G., Weichenhan, D., Müller, O., Eckhart, A.D., Katus, H.A., Koch, W.J., Most, P. :
S100A1 gene therapy preserves in vivo cardiac function after myocardial infarction.
Molecular Therapy 12: 1120-1129, 2005.   

Most, P., Boerries, M., Eicher, C., Schweda, C., Völkers, M., Wedel, T., Söllner, S., Katus, H.A., Remppis, A., Aebi, U., Koch, W.J., Schoenenberger, C. : 
Distinct subcellular location of the Ca2+-binding protein S100A1 differentially modulates Ca2+-cycling in ventricular rat cardiomyocytes.
Journal of Cell Science 118: 421-431, 2005

Most, P.*, Kettlewell, S.*, Currie, S., Koch, W.J., Smith, G.L.: 
S100A1 increases the gain of excitation-contraction coupling in isolated rabbit ventricular cardiomyocytes.
Journal of Molecular and Cellular Cardiology 39: 900-910, 2005. (*shared first authorship) 

Most, P., Pleger, S.T., Völkers, M., Heidt, B., Börries, M., Weichenhan, D., Löffler, E., Janssen, P.M.L., Williams, M.L., Katus, H.A., Remppis, A., Koch, W.J.: 
Cardiac adenoviral S100A1 gene delivery rescues failing myocardium.
Journal of Clinical Investigation 114: 1550-1563, 2004.

Liu, H.R., Gao, E., Hu, A., Tao, L., Qu, Y., Most, P., Koch, W.J., Christopher, T.A., Lopez, B.L., Alnemri, E.S., Zervos, A.S., Ma, X.L.:
Role of Omi/HtrA2 in apoptotic cell death after myocardial ischemia and reperfusion.
Circulation 111: 90-96, 2004.

Remppis, A., Pleger, S.T., Most, P., Lindenkamp, J., Ehlermann, P., Schweda, C., Löffler, E., Weichenhan, D., Zimmermann, W., Eschenhagen, T., Koch, W.J., Katus, H.A.: 
S100A1 gene transfer: A strategy to strengthen engineered cardiac grafts.
Journal of  Gene Medicine 6: 387-394, 2004.

Most, P., Börries, M., Eicher, C., Schweda, C., Löffler, E., Ehlermann, P., Pleger, S.T., Koch, W.J., Katus, H.A., Remppis, A.: 
Extracellular S100A1 protein inhibits apoptosis of ventricular rat cardiac myocytes via activation of the ERK1/2 pathway.
Journal of  Biological Chemistry 278: 48404-48412, 2003.

Most, P., Remppis, A., Pleger, S.T., Loffler, E., Ehlermann, P., Bernotat, J., Kleuss, C., Heierhorst, J., Ruiz, P., Witt, H., Karczewski, P., Mao, L., Rockman, H.A., Duncan, S.J., Katus, H.A., Koch, W.J.: 
Transgenic overexpression of the Ca2+ binding protein S100A1 in the heart leads to increased in vivo myocardial contractile performance.
Journal of  Biological Chemistry 278: 33809-33817, 2003. 

Most, P., Remppis, A., Weber, C., Bernotat, J., Ehlermann, P., Pleger, S.T., Kirsch, W., Weber, M., Uttenweiler, D., Smith, G.L., Katus, H.A., Fink, R.H.: 
The C-terminus (aa 75-94) and the linker region (aa 42-54) of the Ca2+ binding protein S100A1 differentially enhance sarcoplasmic Ca2+ release in murine skinned skeletal muscle fibres.
Journal of  Biological Chemistry 278: 26356-26364, 2003.

Most, P. and Koch, W.J.: 
Sealing the leak, healing the heart.
Nature Medicine 9: 993-994, 2003. 

Remppis, A., Most, P., Löffler, E., Ehlermann, P., Bernotat, J., Pleger, S., Börries, M., Reppel, M., Fischer, J., Koch, W.J., Smith, G.L., Katus, H.A.:
The small EF-hand Ca2+ binding protein S100A1 increases contractility and Ca2+ cycling in rat cardiac myocytes.
Basic Res Cardiol 97: I/56-I/62, 2002. 

Most, P., Bernotat, J., Ehlermann, P., Pleger, S.T., Reppel, M., Börries, M., Niroomand, F., Pieske, B., Janssen, P.M.L., Eschenhagen, T., Karczewski, P., Smith, G.L., Koch, W.J., Katus, H.A., Remppis, A.: 
S100A1: A regulator of myocardial contractility.
Proc Natl Acad Sci U S A 98: 13889-13894, 2001. 

Remppis, A., Ehlermann, P., Giannitsis, E., Greten, T., Most, P., Müller-Bardorff, M., Katus, H.A.:
Cardiac Troponin T Levels at 96 Hours Reflect Myocardial Infarct Size ‑ a Pathoanatomical Study.
Cardiology 93: 249‑253, 2000.

Ehlermann, P., Remppis, A., Most, P., Bernotat, J., Heizmann, C.W., Katus, H. A.:
Purification of the Ca2+ binding protein S100A1 from myocardium and recombinant Escherichia coli.
J Chromatogr B Biomed Sci App 737: 39‑45, 2000.